Nebraska Center for Nanomedicine- Bioimaging Core

内布拉斯加州纳米医学中心 - 生物成像核心

• 批准号: 10163873
• 负责人: Yutong Liu
• 金额: $ 28.21万
• 依托单位: UNIVERSITY OF NEBRASKA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-06-01 至 2023-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10163873
• 关键词: Address; Adhesions; Anatomy; Animals; Antibodies; Binding; Biochemical; Biodistribution; Bioinformatics; Biological Markers; Biology; Blood Vessels; Blood flow; Brain; Cancer Center; Cardiac; Cardiovascular Diseases; Cells; Cellular biology; Centers of Research Excellence; Chronic; Collaborations; Communities; Computer software; Contrast Media; Core Facility; Custom; Data; Databases; Detection; Development; Developmental Biology; Disease; Drug Delivery Systems; Dyes; Equipment; Evaluation; Expenditure; Fees; Fertilization; Frequencies; Funding; Goals; Grant; Hemoglobin; Human; Hypoxia; Image; Imaging Device; Immunology; Individual; Institution; Label; Lasers; Letters; Link; Magnetic Resonance Imaging; Methodology; Methods; Microscope; Molecular Probes; Monitor; Nano delivery; Nebraska; Neoplasms in Vascular Tissue; Neurobiology; Operating System; Optics; Organ; Output; Oxygen; Pathway interactions; Perfusion; Phase; Physiological; Physiology; Pre-Clinical Model; Process; Proteins; Research; Research Personnel; Resolution; Rodent; Rodent Model; Scheme; Services; Sonication; Statistical Data Interpretation; Stress; Structure; System; Technology; Tissues; Training; Tumor Biology; Ultrasonography; Visual; Visualization; Work; angiogenesis; animal imaging; base; bioimaging; cancer imaging; cell motility; clinical application; data warehouse; efficacy evaluation; experience; experimental study; fluorophore; heart function; hemodynamics; image processing; imaging facilities; imaging modality; imaging system; in vivo; insight; instrument; instrumentation; intravital microscopy; longitudinal animal study; nanomaterials; nanomedicine; nanoparticle; novel therapeutics; organizational structure; photoacoustic imaging; pre-clinical; quantitative imaging; response; senior faculty; tool; tumor; tumor growth

ABSTRACT Bioimaging is an essential research tool. The ability for high fidelity anatomical localization of proteins and nanodelivery agents is an indispensable component in the development of new therapeutics. Furthermore, new imaging modalities allow for a highly sensitive way of binding structure to function with high resolution in small animals. As such, we will utilize a single Core structure to house three instruments that will be utilized by investigators associated with this COBRE. Small animal magnetic resonance imaging (MRI) will be available using two preclinical 7 Tesla MRI scanners, one Bruker Biospec 7T/21cm MRI/MRS system operating Avance III hardware and one Bruker Pharmascan system (7T/16 cm). High frequency ultrasound (up to 40 MHz) alone and combined with photoacoustic laser imaging will use the Visual Sonics 2100 and 3100 instruments equipped with the LAZR-X technology. Finally, a new state-of-the-art intravital microscopy system includes an Olympus FVMPE-RS multiphoton laser confocal microscope with 2 line lasers. The bioimaging core will be directed by three experienced senior faculty who have been associated with this COBRE for many years. The Core directors will oversee the function of each piece of instrumentation and direct technical staff. In association with Core they will monitor expenditures and recommend adjustments in user fees as necessary. Importantly, the Bioimaging Core will provide essential training to the investigators for specific uses. Given the capabilities of these instruments, it is anticipated that a wide variety of studies will take place related to nanomedicine. This includes nanoparticle biodistribution, cell tracking, hemoglobin saturation, blood flow, antibody adhesion, cardiac and vascular function, angiogenesis and live vascular and tumor imaging. Based on current grant support we estimate a continuously active Core that will grow in use. The Core will be actively engaged in the development of new imaging tools and unique ways of advancing investigators' research. A key component in the administration of this Core is insuring its sustainability beyond Phase III. Outstanding institutional support combined with adjustment of user fees will provide long-term funding. RELEVANCE Non-invasive evaluation using clinically applicable imaging methods is a critical step in the translational pathway towards human use of nanomedicines. Access to experts in imaging and state-of-the-art equipment will allow for training new investigators in the use of quantitative in-vivo methodologies and the important details to be addressed when planning such experiments.

抽象的 生物成像是必不可少的研究工具。蛋白质和 纳米传递剂是开发新疗法的必不可少的组成部分。此外，新的 成像方式允许一种高度敏感的结构方式，可以在小分辨率中发挥高分辨率 动物。因此，我们将利用一个核心结构来容纳三种将由 与此毛绒相关的调查人员。小动物磁共振成像（MRI）将提供 使用两个临床前7个Tesla MRI扫描仪，一个Bruker Biospec 7T/21cm MRI/MRS系统操作Avance III硬件和一个Bruker Pharmascan系统（7T/16厘米）。高频超声（最多40 MHz） 并与光声激光成像结合使用，将使用视觉超音速2100和3100仪器 配备LAZR-X技术。最后，一个新的最新浸润显微镜系统包括 Olympus FVMPE-RS多光子激光共聚焦显微镜，带有2行激光器。生物成像核心将是 由三个经验丰富的高级教师执导，他们与这家人有很多年。这 核心主管将监督每个仪器和直接技术人员的功能。在 与核心相关联，他们将监控支出，并建议根据需要进行调整。 重要的是，生物成像核心将为调查人员提供特定用途的基本培训。鉴于 这些乐器的功能，预计将进行各种各样的研究 纳米医学。这包括纳米颗粒生物分布，细胞跟踪，血红蛋白饱和，血流， 抗体粘附，心脏和血管功能，血管生成以及活血管和肿瘤成像。基于 在当前的赠款支持下，我们估计将在使用中增长的连续活跃核心。核心将积极 从事新成像工具的开发以及推进研究人员研究的独特方法。钥匙 该核心管理的组成部分正在确保其可持续性超出第三阶段。杰出的 机构支持加上调整用户费用将提供长期资金。 关联 使用临床上适用的成像方法的非侵入性评估是翻译的关键步骤 人类使用纳米医学的途径。访问成像和最先进设备的专家 将允许培训新的研究人员使用定量体内方法和重要的 在计划此类实验时要解决的详细信息。